Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients

Zygimantas C. Alsauskas, Raj Kiran Medapalli, Michael J. Ross

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: Human immunodeficiency virus (HIV) infection is associated with the development of a wide spectrum of kidney diseases. HIV-associated nephropathy (HIVAN) is the most common cause of chronic kidney disease (CKD) in HIV-infected individuals and predominantly affects patients of African ancestry. HIVAN is a leading cause of end-stage renal disease (ESRD) among African-Americans. Areas covered: An overview of the spectrum of kidney disease in patients with HIV is given. Current pharmacologic interventions to treat kidney disease in HIV are discussed. This review will enhance knowledge regarding the most common causes of kidney disease in HIV-infected patients. An understanding of the principles related to pharmacotherapy in HIV-infected patients with kidney disease will also be gained. Expert opinion: Kidney disease is an important cause of morbidity and mortality in HIV-infected patients. The most common cause of chronic kidney disease in this population is HIV-associated nephropathy, which is caused by viral infection of the renal epithelium. Several medications that are commonly used in HIV-infected patients can have adverse effects on the kidneys and the doses of many antiretroviral medications need to be adjusted in patients with impaired renal function.

Original languageEnglish (US)
Pages (from-to)691-704
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number5
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Expert Testimony
Kidney Diseases
HIV
Drug Therapy
AIDS-Associated Nephropathy
Virus Diseases
Chronic Renal Insufficiency
Kidney
African Americans
Chronic Kidney Failure
Epithelium
Morbidity
Mortality
Population

Keywords

  • antiretroviral therapy
  • collapsing glomerulopathy
  • FSGS
  • HIV-associated nephropathy
  • HIVAN

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. / Alsauskas, Zygimantas C.; Medapalli, Raj Kiran; Ross, Michael J.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 5, 04.2011, p. 691-704.

Research output: Contribution to journalReview article

Alsauskas, Zygimantas C. ; Medapalli, Raj Kiran ; Ross, Michael J. / Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 5. pp. 691-704.
@article{8bfd70a8e39f445994762457fd53327b,
title = "Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients",
abstract = "Introduction: Human immunodeficiency virus (HIV) infection is associated with the development of a wide spectrum of kidney diseases. HIV-associated nephropathy (HIVAN) is the most common cause of chronic kidney disease (CKD) in HIV-infected individuals and predominantly affects patients of African ancestry. HIVAN is a leading cause of end-stage renal disease (ESRD) among African-Americans. Areas covered: An overview of the spectrum of kidney disease in patients with HIV is given. Current pharmacologic interventions to treat kidney disease in HIV are discussed. This review will enhance knowledge regarding the most common causes of kidney disease in HIV-infected patients. An understanding of the principles related to pharmacotherapy in HIV-infected patients with kidney disease will also be gained. Expert opinion: Kidney disease is an important cause of morbidity and mortality in HIV-infected patients. The most common cause of chronic kidney disease in this population is HIV-associated nephropathy, which is caused by viral infection of the renal epithelium. Several medications that are commonly used in HIV-infected patients can have adverse effects on the kidneys and the doses of many antiretroviral medications need to be adjusted in patients with impaired renal function.",
keywords = "antiretroviral therapy, collapsing glomerulopathy, FSGS, HIV-associated nephropathy, HIVAN",
author = "Alsauskas, {Zygimantas C.} and Medapalli, {Raj Kiran} and Ross, {Michael J.}",
year = "2011",
month = "4",
doi = "10.1517/14656566.2011.535518",
language = "English (US)",
volume = "12",
pages = "691--704",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients

AU - Alsauskas, Zygimantas C.

AU - Medapalli, Raj Kiran

AU - Ross, Michael J.

PY - 2011/4

Y1 - 2011/4

N2 - Introduction: Human immunodeficiency virus (HIV) infection is associated with the development of a wide spectrum of kidney diseases. HIV-associated nephropathy (HIVAN) is the most common cause of chronic kidney disease (CKD) in HIV-infected individuals and predominantly affects patients of African ancestry. HIVAN is a leading cause of end-stage renal disease (ESRD) among African-Americans. Areas covered: An overview of the spectrum of kidney disease in patients with HIV is given. Current pharmacologic interventions to treat kidney disease in HIV are discussed. This review will enhance knowledge regarding the most common causes of kidney disease in HIV-infected patients. An understanding of the principles related to pharmacotherapy in HIV-infected patients with kidney disease will also be gained. Expert opinion: Kidney disease is an important cause of morbidity and mortality in HIV-infected patients. The most common cause of chronic kidney disease in this population is HIV-associated nephropathy, which is caused by viral infection of the renal epithelium. Several medications that are commonly used in HIV-infected patients can have adverse effects on the kidneys and the doses of many antiretroviral medications need to be adjusted in patients with impaired renal function.

AB - Introduction: Human immunodeficiency virus (HIV) infection is associated with the development of a wide spectrum of kidney diseases. HIV-associated nephropathy (HIVAN) is the most common cause of chronic kidney disease (CKD) in HIV-infected individuals and predominantly affects patients of African ancestry. HIVAN is a leading cause of end-stage renal disease (ESRD) among African-Americans. Areas covered: An overview of the spectrum of kidney disease in patients with HIV is given. Current pharmacologic interventions to treat kidney disease in HIV are discussed. This review will enhance knowledge regarding the most common causes of kidney disease in HIV-infected patients. An understanding of the principles related to pharmacotherapy in HIV-infected patients with kidney disease will also be gained. Expert opinion: Kidney disease is an important cause of morbidity and mortality in HIV-infected patients. The most common cause of chronic kidney disease in this population is HIV-associated nephropathy, which is caused by viral infection of the renal epithelium. Several medications that are commonly used in HIV-infected patients can have adverse effects on the kidneys and the doses of many antiretroviral medications need to be adjusted in patients with impaired renal function.

KW - antiretroviral therapy

KW - collapsing glomerulopathy

KW - FSGS

KW - HIV-associated nephropathy

KW - HIVAN

UR - http://www.scopus.com/inward/record.url?scp=79952592813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952592813&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.535518

DO - 10.1517/14656566.2011.535518

M3 - Review article

C2 - 21250871

AN - SCOPUS:79952592813

VL - 12

SP - 691

EP - 704

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -